Impact of PharmaNet-Based Admission Medication Reconciliation on Best Possible Medication Histories for Warfarin

Debbie Au, Hilary Wu, Cindy San, Doson Chua, Victoria Su, and Allison Kirkwood

ABSTRACT

Background: Inaccurate documentation of medication histories may lead to medication discrepancies during hospital admissions. Obtaining a best possible medication history (BPMH) for warfarin can be challenging because of frequent dosage changes and nonspecific directions of use (e.g., “take as directed”). On February 27, 2012, the study hospital implemented an admission medication reconciliation (MedRec) process using a form that compiled the most recent 6 months of outpatient prescription dispensing history from a provincial electronic database called PharmaNet. It was unclear whether admission MedRec had improved the process of obtaining warfarin BPMHs and the quality of their documentation.

Objective: To compare the rates of complete warfarin BPMH documentation before and after implementation of PharmaNet-based admission MedRec.

Methods: A single-centre, retrospective chart review was conducted using the health records of patients receiving warfarin who were admitted to the hospital’s Internal Medicine service before and after implementation of admission MedRec. The study periods were October 1, 2009, to February 26, 2012, and February 27, 2012, to July 31, 2014, respectively.

Results: Data were recorded for 100 patients in the pre-implementation phase and 100 patients in the post-implementation phase. The rates of complete warfarin BPMH documentation were 65% and 84% in these 2 phases, respectively ($p = 0.002$).

Conclusion: Implementation of PharmaNet-based admission MedRec was associated with a statistically significant increase in the rate of complete warfarin BPMH documentation.

Keywords: warfarin, medication reconciliation, PharmaNet, best possible medication history

INTRODUCTION

Obtaining an accurate and complete medication history is essential for patient safety. In their systematic review, Tam and others concluded that errors in prescription medication histories occurred in up to 67% of admissions. Of these errors, 39% were deemed to have the potential to cause moderate to severe harm as a result of unintentional changes to medication regimens.2

To address medication errors in hospitals, Accreditation Canada established a Required Organizational Policy in 2010 stating that medication reconciliation (MedRec) must be completed at the time of hospital admission.3 MedRec upon admission involves interviewing the patient and/or caregiver to obtain a best possible medication history (BPMH) of medications that were being taken before admission. This BPMH informs decisions about continuing, discontinuing, or changing the patient’s medication regimen while in hospital.3

A lack of consistent BPMH documentation and variation in the MedRec process among clinicians can be problematic. In British Columbia, obtaining a BPMH is supported by the use of records from PharmaNet, an electronic database of all outpatient prescriptions dispensed in the province in the preceding 14 months, except for antiretroviral medications. On February 27, 2012, the study hospital, a tertiary institution in British Columbia, implemented admission MedRec using a PharmaNet-based form (Figure 1). This form compiled the medication dispensing history for the previous 6 months, as recorded in PharmaNet. The intent of the admission MedRec form was to assist physicians in reordering prior-to-admission medications and to minimize the risk of unintentional medication discrepancies and associated harm.

An accurate and complete MedRec process is critical for patients who are receiving warfarin. This anticoagulant has wide interpatient variation in dosing, and dosage adjustments are often interpatient variation in dosing, and dosage adjustments are often required to achieve the target international normalized ratio (INR).4 Consequently, physicians rely on the BPMH to determine the appropriate warfarin dose for each admitted patient. However, obtaining warfarin BPMHs using PharmaNet records can be challenging, because the database records often contain nonspecific directions for use, such as “Take as directed” or “Doctor to adjust dose based on INR”. Therefore, relying on PharmaNet alone to obtain warfarin BPMHs may lead to incomplete histories of warfarin use and the prescription of inappropriate warfarin dosages upon admission to hospital. These problems may delay achievement of target INR and increase the risk of warfarin-related adverse events because of subtherapeutic or supratherapeutic INR.5,6 In a study of patients 65 years of age or older, hemorrhagic and thromboembolic risks were strongly associated with intensity of anticoagulation.5 Rates of bleeding increased 19-fold when the INR was supratherapeutic, and rates of thromboembolic events increased 7-fold when the INR was subtherapeutic.5 The Institute for Safe Medication Practices (US) has classified warfarin as a high-alert medication in the acute care setting.5

The purpose of this study was to evaluate the impact of PharmaNet-based admission MedRec on obtaining complete warfarin BPMHs.

METHODS

Design

This single-centre, retrospective chart review was approved by the UBC–Providence Health Care Research Ethics Board. The need for informed consent was waived.

Study Population

The study used a convenience sample of 100 patients in each phase who met the study’s inclusion criteria. Patients were screened for eligibility using information in the hospital pharmacy database and patients’ charts. Patients were included if they were 18 years of age or older, had been taking warfarin before admission, and had been admitted to the Internal Medicine service of the study hospital between October 1, 2009, and July 31, 2014 (pre-implementation phase: October 1, 2009, to February 26, 2012; post-implementation phase: February 27, 2012 to July 31, 2014).

The following exclusion criteria were applied: patient was a nonresident of British Columbia and would therefore not have a PharmaNet record; no MedRec form was completed in the post-implementation phase; patient was discharged or transferred to another facility within 24 h after admission; patient was admitted from another facility, was transferred to an intensive care unit during the admission, or underwent surgery during the admission; or patient was admitted with a thromboembolic or major bleeding event. Thromboembolic events were defined as ischemic stroke, transient ischemic attack, systemic embolism, deep vein thrombosis, or pulmonary embolism. Major bleeding events were defined as bleeding events that were fatal, intracranial, intraspinal, intraocular, or retroperitoneal; bleeding events that caused a decrease in hemoglobin of 20g/L or more; or bleeding that necessitated transfusion or required operation.9 Thromboembolic and major bleeding events were identified by reviewing progress notes and discharge summaries in patients’ charts. Any identified events were further verified by reviewing radiologic imaging results, relevant laboratory data, and transfusion records.

Outcomes

The primary outcome was the rate of complete warfarin BPMH documentation upon admission. In the pre-implementation phase, complete warfarin BPMH documentation was defined as documentation of a warfarin regimen specifying both dose and frequency of administration on the admission note. In the
Figure 1. Extract from a sample PharmaNet-Based medication reconciliation form completed at the time of admission.
post-implementation phase, complete warfarin BPMH documentation was defined as documentation of a warfarin regimen specifying both dose and frequency of administration on the MedRec form, the admission note, or both.

**Data Collection**

Data were collected from the hospital’s electronic clinical databases and health records. The following data were collected for each patient: demographic characteristics, the prior-to-admission warfarin regimen as documented on the admission note and/or the MedRec form, the length of hospital stay, and any thromboembolic or major bleeding events that occurred during the admission. For patients in the post-implementation group, warfarin regimens with unclear directions in the PharmaNet database (e.g., “Take as directed”) were also recorded.

**Statistical Analysis**

All statistical analyses were performed using the XLSTAT software package for Microsoft Excel (Microsoft Corporation, Redmond, Washington).

In the primary outcome analysis, the pre- and post-implementation rates of complete warfarin BPMH documentation were compared with the χ² test.

In addition, data from the post-implementation phase were analyzed to assess the influence of PharmaNet records on the MedRec process. More specifically, the χ² test was used to compare the rates of complete warfarin BPMH documentation on the MedRec form between patients with clear versus unclear (e.g., “Take as directed”) warfarin regimens in the PharmaNet database.

It was observed that clinicians commonly documented the dose but not the frequency of administration for warfarin, which we assumed was because warfarin was to be given once daily. Therefore, in a post hoc analysis, the χ² test was also used to compare pre- and post-implementation rates of BPMH documentation considering only the documentation of warfarin dose.

For all statistical analyses, p values less than 0.05 were considered statistically significant.

**RESULTS**

A total of 543 patients were screened, of whom 100 patients were included in the pre-implementation phase and 100 patients in the post-implementation phase (Figure 2). The demographic and clinical characteristics were similar between the 2 groups (Table 1).

The rate of complete warfarin BPMH documentation (with a record of both dose and frequency of administration) was significantly higher in the post-implementation phase than the pre-implementation phase (84% versus 65%, \( p = 0.002 \)) (Table 2). In the post hoc comparison based on documentation of only the dose of warfarin, there was a smaller but nonetheless statistically significant increase in the rate of complete warfarin BPMH documentation after MedRec was implemented (81% versus 91%, \( p = 0.042 \)).

Of the 100 patients included in the post-implementation phase, 38 had unclear warfarin regimens in the PharmaNet database, and 62 had clear regimens. Complete warfarin BPMHs were documented on the MedRec form for 11 (29%) of the 38 patients with unclear PharmaNet records and 54 (87%) of the 62 patients with clear PharmaNet records (\( p < 0.001 \)) (Figure 3). For 23 (61%) of the 38 patients with unclear warfarin regimens in the PharmaNet database, the clinician checked off the “per PharmaNet” box on the MedRec form (Figure 1), thereby indicating that the patient’s prior-to-admission regimen was consistent with the PharmaNet record; the resulting BPMH was thus incomplete.

The rates of thromboembolic and major bleeding events during the hospital stay were similar between the pre- and post-implementation phases (0% versus 0% for thromboembolic events and 2% versus 1% for major bleeding events). The mean length of hospital stay was also similar for the 2 phases (Table 1).

**DISCUSSION**

The goal of implementing PharmaNet-based admission MedRec was to facilitate a systematic approach to gathering and documenting BPMHs, to prevent duplication of work across disciplines, and to consolidate BPMH documentation into one consistent location within the patient chart.\(^\text{10}\)

Obtaining a complete and accurate BPMH is essential to preventing drug-related problems during hospital admission,\(^\text{11}\) and previous studies evaluating electronically generated medication checklists or MedRec systems have shown a reduction in medication discrepancy rates.\(^\text{12-15}\) Obtaining a complete BPMH is especially important for patients who are taking warfarin, because the complete BPMH serves as a clear record of the patient’s home regimen and allows the clinician to make informed decisions when adjusting the dosage on the basis of INR results.

This study evaluated the impact of PharmaNet-based admission MedRec by comparing the rates of complete warfarin BPMH documentation before and after its implementation. The results indicated a statistically significant increase in the rate of complete warfarin BPMH documentation after MedRec was implemented. These observations suggest that the MedRec form improved BPMH documentation, and it is likely that such improvements will be helpful for clinicians caring for patients in hospital.

Although the study results indicated that integration of PharmaNet records into the MedRec form was useful for BPMH documentation, analysis of the post-implementation data showed that the clarity of warfarin instructions provided in the PharmaNet database influenced the quality of warfarin BPMHs.
352

Figure 2. Patient enrolment in the study and reasons for exclusion. ICU = intensive care unit.

Table 1. Demographic and Clinical Characteristics of Study Participants

<table>
<thead>
<tr>
<th>Characteristic</th>
<th>Phase of Study; % of Patients*</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>Before MedRec Implementation</td>
</tr>
<tr>
<td></td>
<td>(n = 100)</td>
</tr>
<tr>
<td>Age (years) (median and IQR)</td>
<td>73 (63–84)</td>
</tr>
<tr>
<td>Sex, male</td>
<td>60</td>
</tr>
<tr>
<td>Spoken language, English</td>
<td>76</td>
</tr>
<tr>
<td>Length of stay (days) (mean ± SD)</td>
<td>9 ± 7</td>
</tr>
<tr>
<td>No. of home medications (median and IQR)</td>
<td>10 (7–13)</td>
</tr>
<tr>
<td>Indication for warfarin</td>
<td></td>
</tr>
<tr>
<td>Atrial fibrillation</td>
<td>75</td>
</tr>
<tr>
<td>Venous thromboembolism</td>
<td>11</td>
</tr>
<tr>
<td>Replacement of mechanical valve</td>
<td>10</td>
</tr>
<tr>
<td>Other†</td>
<td>4</td>
</tr>
</tbody>
</table>

IQR = interquartile range, MedRec = medication reconciliation, SD = standard deviation.
*Except where indicated otherwise.
†Prior transient ischemic attack, prior left ventricle thrombus, peripheral vascular disease.
PharmaNet records with nonspecific directions for warfarin administration were associated with higher rates of warfarin BPMHs that lacked documentation of the dose or frequency of administration. For most patients with incomplete warfarin BPMHs, the incomplete documentation was a direct result of reliance on unclear PharmaNet records. Specifically, the clinician documented on the MedRec form that the patient was taking warfarin as per the directions on PharmaNet, but those PharmaNet instructions were unclear. This finding suggests that there may be overreliance on PharmaNet records, rather than interviews with the patient or caregiver, when obtaining BPMHs.

British Columbia’s PharmaNet database offers clinicians an additional resource when obtaining BPMHs. However, it is only a dispensing record and may not represent actual home use of medications. Therefore, clinicians must verify the accuracy of PharmaNet information when obtaining the BPMH. This requirement was confirmed by a study conducted in 2005 and 2006, which reported that the availability of PharmaNet did not lower the rate of unintentional medication discrepancies upon admission to a BC hospital relative to the rate in an Ontario hospital, where a provincial prescription database was not available (60% versus 54%). Furthermore, a study conducted in 2003 at St Paul’s Hospital in Vancouver showed a 71% discrepancy rate between medication histories based on information in PharmaNet and those obtained by pharmacists during patient interviews. Therefore, although PharmaNet is an accessible resource for BC clinicians, vigilance is required when reviewing PharmaNet records, particularly by clinicians who are obtaining warfarin BPMHs. In a study conducted in 2011, which compared regimens recorded in BPMHs obtained by pharmacists with regimens recorded in PharmaNet, warfarin had the fourth highest rate of discrepancies: 82.5% of the PharmaNet records for warfarin had dosage errors, frequency errors, and/or unclear instructions.

In addition to overreliance on PharmaNet records, lack of time, staffing resources, and training may contribute to incomplete BPMHs. MedRec at the tertiary hospital where this study was conducted is performed primarily by admitting physicians, with further review by pharmacists. Pharmacists are medication experts and could be valuable assets to the clinical team in

### Table 2. Data for Primary Outcome: Completeness of Warfarin BPMH Documentation

<table>
<thead>
<tr>
<th>Information Recorded in BPMH</th>
<th>Phase of Study; % of Patients*</th>
<th>p Value</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>Before MedRec Implementation (n = 100)</td>
<td>After MedRec Implementation (n = 100)</td>
</tr>
<tr>
<td>Dose</td>
<td>81</td>
<td>91</td>
</tr>
<tr>
<td>Frequency</td>
<td>66</td>
<td>86</td>
</tr>
<tr>
<td>Both dose and frequency*</td>
<td>65</td>
<td>84</td>
</tr>
</tbody>
</table>

BPMH = best possible medication history, MedRec = medication reconciliation.

*This constitutes complete warfarin BPMH documentation.
conducting MedRec during admission. In previous studies, pharmacist-acquired BPMHs were more accurate, were more likely to include nonprescription products, and increased MedRec completion rates for admitted patients relative to those acquired by physicians or nurses.\textsuperscript{19,25} Instead of pharmacists retrospectively clarifying medication discrepancies, early involvement of pharmacists in the MedRec process is a more proactive approach to minimizing medication errors and improving the efficiency of order processing. A cost-effectiveness analysis confirmed that pharmacist-led MedRec had the highest expected net benefits among interventions used to reduce medication errors at admission.\textsuperscript{26} There is currently no formalized process for pharmacists to conduct MedRec at the study hospital, although efforts are made to obtain BPMHs for high-risk patients with multiple comorbidities and/or multiple medications before admission. Incorporating pharmacy technicians into the admission MedRec process would be a feasible option to make such pharmacy services available to more patients. Multiple studies have shown that, with proper training, pharmacy technicians can collect complete and accurate BPMHs while identifying medication discrepancies for pharmacists to resolve as necessary.\textsuperscript{24,25,27}

This study had several limitations. First, because of the retrospective nature of the study, it was not possible to verify the accuracy of the documented warfarin BPMHs. Furthermore, it was not possible to interview the clinicians to determine their methods of obtaining medication histories and to confirm the reasons for incomplete BPMH documentation. Finally, the sample size was insufficient to assess the effect of MedRec on warfarin-related clinical outcomes, such as thromboembolic and bleeding events. Therefore, future larger studies are needed to evaluate the accuracy of BPMH documentation, to determine the challenges of using the MedRec form, and to examine the utility of MedRec with regard to clinical outcomes.

**CONCLUSION**

In this study, implementation of PharmaNet-based admission MedRec was associated with a statistically significant increase in the rate of complete warfarin BPMH documentation. This finding suggests that the PharmaNet-based admission MedRec form can be a useful tool in standardizing the MedRec process. However, the clarity of PharmaNet records for warfarin was found to influence the quality of warfarin BPMHs. To ensure that BPMHs accurately reflect patients’ home medication use, clinicians must be aware that PharmaNet records cannot be used as a substitute for BPMH and that PharmaNet records must be verified carefully upon admission to hospital.

**References**


Debbie Au, BSc(Pharm), ACPR, is with Lower Mainland Pharmacy Services, Vancouver General Hospital, Vancouver, British Columbia.

Hilary Wu, BSc(Pharm), ACPR, is with Lower Mainland Pharmacy Services, St Paul's Hospital, Vancouver, British Columbia.

Cindy San, BSc(Pharm), ACPR, PharmD, is with Lower Mainland Pharmacy Services, St Paul's Hospital, Vancouver, British Columbia.

Doson Chua, BSc(Pharm), PharmD, BCPS(AQ), is with Lower Mainland Pharmacy Services, St Paul's Hospital, Vancouver, British Columbia.

Victoria Su, BSc(Pharm), ACPR, PharmD, BCPS, is with Lower Mainland Pharmacy Services, St Paul's Hospital, Vancouver, British Columbia.

Allison Kirkwood, BSc(Pharm), ACPR, is with Lower Mainland Pharmacy Services, St Paul's Hospital, Vancouver, British Columbia.

Competing interests: None declared.

Address correspondence to: Debbie Au
G-42 Ground
Vancouver General Hospital
855 West 12th Avenue
Vancouver BC V5Z 1M9
e-mail: Debbie.au@vch.ca

Funding: None received.

Acknowledgements: The authors would like to acknowledge Stephanie Chan, BSc(Pharm), ACPR, for her expertise in medication reconciliation, and Angela Fung, BSc(Pharm), for assistance in data collection for this study.